# Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

> **NCT03613259** · EARLY_PHASE1 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Stage II Adult Soft Tissue Sarcoma
- Stage IIA Adult Soft Tissue Sarcoma
- Stage IIB Adult Soft Tissue Sarcoma
- Stage IIC Adult Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** Fluorothymidine F-18
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT03613259
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding expired
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03613259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03613259, "Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03613259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*